#Israel #Rehovot #Evogene #ChemPass AI #Pure Capital Group

Evogene and Pure Capital Group Join Forces for a Strategic Agreement

In a significant move aimed at establishing long-term operational stability, Evogene Ltd. has announced a comprehensive cooperation agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., collectively referred to as the Pure Capital Group. This latest development is crucial for Evogene, a pioneering company in computational chemistry, as it focuses on harnessing artificial intelligence for the discovery and optimization of small molecules in both pharmaceutical and agricultural industries.

Background of the Agreement

The announcement follows recent tensions between Evogene and the Pure Capital Group, which arose after the Annual General Meeting held on September 4, 2026. Claims regarding the voting results asserted by the Pure Capital Group prompted them to consider initiating a special tender offer to gain more control over the company's board. Faced with the prospect of a protracted legal battle, both parties opted for negotiations, leading to the current agreement that promises to benefit not just the company but also its shareholders.

Key Features of the Cooperation Agreement

The agreement stipulates several important changes to Evogene’s board of directors. Dr. Yael Margolin and Mr. Yoshinori Oikawa, both current directors, are set to be replaced by nominees from the Pure Capital Group, Dr. Adi Zuluf-Shani and Mr. Oz Adler. Following the execution of the agreement, a general shareholders meeting will be called to formalize these changes and vote on other critical elements, including mutual waivers and non-disparagement covenants.

In total, the restructured board will consist of seven members, including four from the Pure Capital Group, ensuring a significant influence in steering Evogene's future. Alongside this, the agreement includes a 60-day standstill period where the Pure Capital Group will retract its notice regarding the tender offer, allowing Evogene room to operate without the pressures of imminent shareholder disputes.

The Shift Towards Stability and Growth

With this restructuring, Evogene and the Pure Capital Group aim to focus on their shared vision of innovation and leadership in AI-driven drug development and agricultural solutions. The cooperation agreement is expected to enhance operational efficiency and provide Evogene with the strategic stability necessary to push forward its business strategies and technological development centered around its proprietary ChemPass AI™ technology.

Evogene stands at the forefront of utilizing AI to streamline the process of molecule discovery, aiming to create highly effective drug candidates and ag-chemical products. This move, therefore, is not just a step toward calming immediate conflicts but a proactive approach to positioning themselves as leaders in their respective fields.

Moving Forward

As Evogene prepares for the global meeting of shareholders, the company’s commitment remains clear: to steer the ship towards transformative discoveries that benefit both healthcare and agricultural sectors. The agreement with the Pure Capital Group could very well represent a pivotal moment in this journey, as the company seeks to leverage its technological prowess amid the evolving landscape of drug design methodologies.

In conclusion, the partnership between Evogene and Pure Capital Group not only signifies a resolution to current disputes but also signals a strategic move towards leveraging AI for groundbreaking developments in drug and agricultural technologies, setting a promising stage for the future of both entities involved.